Efficacy and Safety of Hou Gu Mi Xi in Patients With Peptic Ulcer Diseases

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This trial aims to determine whether Jiangzhong Hou Gu® Mi Xi™ is an effective intervention to improve symptoms and indicators in patients with spleen qi deficiency and peptic ulcer diseases.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jiangxi University of Traditional Chinese Medicine
• Collaborators: Fengcheng Hospital of Traditional Chinese Medicine; Fengcheng People's Hospital; Jiangxi Hospital of Traditional Chinese Medicine; Jiujiang Hospital of Traditional Chinese Medicine; Jiujiang No.1 People's Hospital; Nanchang Hongdu Hospital of Traditional Chinese Medicine; Nanchang Hospital of Integrated Traditional Chinese and Western Medicine; Second Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University; The Nanchang Third Hospital; The Third Affiliated Hospital of Nanchang University; Xinyu Hospital of Traditional Chinese Medicine; Xinyu People's Hospital
• Treatments: Potassium Citrate; Rabeprazole

Criteria

Inclusion Criteria:

1. Patient should be diagnosed as gastric or duodenal ulcer under endoscope; the diameter of ulcers range from 0.3 to 1.0 cm; no indicator of bleeding or perforation.

2. Patient should be diagnosed as syndrome of spleen qi deficiency, that is, meet 2 main symptoms of spleen deficiency and 2 main symptoms of qi deficiency, or have 2 main symptoms of spleen deficiency, 1 main symptoms of qi deficiency and tongue symptoms as follow:

• Main symptoms of spleen deficiency: a) poor appetite; b) abnormal stool (loose, diarrhea); c) abdominal distention after meal or at afternoon

• Main symptoms of qi deficiency: a) fatigue and weak; b) tired mind and taciturnity

• Secondary symptoms: a) tastelessness, hypodipsia, like hot drink, or polysialia; b) abdominal pain, as a result either patients like warm or press; pain remits after meal or occurs when work; c) nausea and vomiting; d) tightness in stomach; e) abnormal bowel sounds; f) lean or puffiness; g) sallow complexion; h) powerless defecation weakness; i) edema

• Tongue symptoms: pale or swollen or teeth-printed tongue with thin and white fur

3. Age is between 18 to 70 years

4. Sign the informed consent

Exclusion Criteria:

1. Patients who have complex peptic ulcer (i.e. have gastric and duodenal ulcer meanwhile)

2. Patients who have history of ulcer complications (e.g. bleeding or perforation)

3. Patients who have indicators of ulcer complications, including bleeding (Forrest stage I, IIa and IIb) or perforation (area of ulcer is more than 1 cm).

4. Patients whose ulcer have healed, that is, the ulcer is at healing stage or scarring stage according to the diagnosis criteria in Consensus View of Integrated Chinese and Western Medicine on Diagnosis and Treatment of Peptic Ulcer (2011, Tianjin)

5. Patients who took proton-pump inhibitor more than 3 days within 15 days, or took non-steroid anti-inflammatory drugs for a long term

6. Female patients who are pregnant or breast-feeding, or prepare to pregnant for pregnancy within 2 years

7. Patients who are allergic to sample or sample composition

8. Patients who are allergic to sample or sample composition

9. Patients who have impaired liver function, including one of following condition: a) total bilirubin > 35 μmol/L; b) alanine transaminase >2 upper limit of normal (ULN); or c) aspartate aminotransferase >2 ULN

10. Patients who have impaired kidney function, that is, serum creatinine >2 ULN

11. Patients who have obviously abnormal electrocardiogram

12. Patients who have stool occult blood, that is, positive result in immunoassay or iron elemental test, and the results continue to be positive after 3 days of vegetarian diet.

13. Patients who undertaken drugs that could damage stomach and intestine, or experienced side effects of dyspepsia for undertaking non-steroidal anti-inflammatory drugs, theophylline, oral antibiotic or potassium supplements within 3 months

14. Patients who are receiving any agents or other intervention for treating his/her gastrointestinal disorder

15. Patients with any malignant tumor

16. Patients who have severe mental disorders so that could not control his/her action and coordinate the treatment in this trial.

17. Patients who are unwilling to provider personal information and enter this trial

18. Patients who cannot understand and sign informed consent